Update on hormone-refractory prostate cancer

被引：30

作者：

Kasamon, KM ^{[1
]}

Dawson, NA ^{[1
]}

机构：

[1] Univ Maryland, Sch Med, Greenbaum Canc Ctr, Baltimore, MD 21201 USA

来源：

CURRENT OPINION IN UROLOGY | 2004年 / 14卷 / 03期

关键词：

androgen-independent prostate cancer; hormone-refractory prostate cancer; prostate cancer;

D O I：

10.1097/00042307-200405000-00008

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Bisphosphonates and chemotherapy are providing effective palliative approaches. Phase II trials of taxane-based regimens show higher response rates and longer survival than has typically been achieved with existing standards. Two completed randomized phase III studies to be reported in mid-2004 will more definitively answer the question of whether currently available chemotherapy can improve survival.

引用

页码：185 / 193

页数：9

共 85 条

[1] ENDOTHELIN INHIBITS OSTEOCLASTIC BONE-RESORPTION BY A DIRECT EFFECT ON CELL MOTILITY - IMPLICATIONS FOR THE VASCULAR CONTROL OF BONE-RESORPTION [J].

ALAM, ASMT ;

GALLAGHER, A ;

SHANKAR, V ;

GHATEI, MA ;

DATTA, HK ;

HUANG, CLH ;

MOONGA, BS ;

CHAMBERS, TJ ;

BLOOM, SR ;

ZAIDI, M .

ENDOCRINOLOGY, 1992, 130 (06) :3617-3624

[2] Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer [J].

Beer, TM ;

Pierce, WC ;

Lowe, BA ;

Henner, WD .

ANNALS OF ONCOLOGY, 2001, 12 (09) :1273-1279

[3] Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer [J].

Beer, TM ;

Eilers, KM ;

Garzotto, M ;

Egorin, MJ ;

Lowe, BA ;

Henner, WD .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) :123-128

[4] Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate [J].

Berry, W ;

Dakhil, S ;

Gregurich, MA ;

Asmar, L .

SEMINARS IN ONCOLOGY, 2001, 28 (04) :8-15

[5] Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer [J].

Berry, W ;

Dakhil, S ;

Modiano, M ;

Gregurich, M ;

Asmar, L .

JOURNAL OF UROLOGY, 2002, 168 (06) :2439-2443

[6]

BERRY WR, 2003, P AN M AM SOC CLIN, V22, P745

[7]

Bok RA, 2001, CANCER RES, V61, P2533

[8] Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group [J].

Bubley, GJ ;

Carducci, M ;

Dahut, W ;

Dawson, N ;

Daliani, D ;

Eisenberger, M ;

Figg, WD ;

Freidlin, B ;

Halabi, S ;

Hudes, G ;

Hussain, M ;

Kaplan, R ;

Myers, C ;

Oh, W ;

Petrylak, DP ;

Reed, E ;

Roth, B ;

Sartor, O ;

Scher, H ;

Simons, J ;

Sinibaldi, V ;

Small, EJ ;

Smith, MR ;

Trump, DL ;

Vollmer, R ;

Wilding, G .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3461-3467

[9] Toward therapeutic intervention of cancer by vitamin D compounds [J].

Campbell, MJ ;

Koeffler, HP .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (03) :182-185

[10] Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: A randomized, phase II, placebo-controlled trial [J].

Carducci, MA ;

Padley, RJ ;

Breul, J ;

Vogelzang, NJ ;

Zonnenberg, BA ;

Daliani, DD ;

Schulman, CC ;

Nabulsi, AA ;

Humerickhouse, RA ;

Weinberg, MA ;

Schmitt, JL ;

Nelson, JB .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (04) :679-689

← 1 2 3 4 5 6 7 8 9 →